StelisBiopharma and Pieris Forge alliance for Novel Anticalin Therapeutics in ophthalmology

Stelis Biopharma (formerly Agila Biotech), a subsidiary of Strides Arcolab, focused on biotherapeutic drug development and bio-manufacturing, and Pieris, a next generation therapeutic protein R&D company, announced the initiation of a long-term collaboration for clinical development and commercialisation of multiple novel Anticalin-based protein therapeutics worldwide, primarily focusing on ophthalmology. The alliance deploys the synergies of Pieris’ innovative drug discovery and early development capabilities with Stelis’ strong bio-manufacturing and clinical development expertise.

Under the terms of the agreement, Pieris will advance each collaborative programme through in vivo proof of concept, at which stage Stelis will be responsible for drug manufacturing and advancing the molecule through a first-in-human clinical study. Following positive clinical data, the parties will co-develop programmes under a joint venture.

Dr Anand Iyer, Chief Executive Officer, Stelis commented, “Our alliance with Pieris demonstrates how Stelis’ strategic investments into state-of-the-art manufacturing facilities are attracting partners with cutting-edge biologics such as Anticalins, which hold great promise in the ophthalmic space.”

Stephen Yoder, Chief Executive Officer, Pieris stated, “Today’s announcement is another example of how Pieris is finding innovative structures and committed partners to advance several Anticalins to the clinic in areas of high unmet need. Our strategic relationship with Stelis provides access to bio-manufacturing capabilities of the highest standard, yet in a very cost-effective manner.”

EP News Bureau-Mumbai